Digital Validation in 2026: What Changed, What Didn’t

Instead, just as that foundation solidified, the AI revolution accelerated everything. And yet here we are.

Digital validation in 2026 feels very different than it did in 2021. The tools are smarter. The systems are more connected. AI isn’t experimental anymore; it’s rapidly being adopted in a variety of ways. Pharma 4.0™, as articulated in ISPE’s Pharma 4.0™ Operating Model and related guidance isn’t a slide in a conference deck anymore: it’s operational reality.

But here’s the interesting part: Some of the most important things haven’t changed at all.

Let’s talk about both.

What Actually Changed

AI Is No Longer “Emerging”

The publication of the ISPE GAMP^® Guide: Artificial Intelligence (2025) was a turning point. It didn’t make AI less complex, but it did make the conversation more structured.

AI systems are still computerized systems but operate as interconnected systems of systems, embedded across platforms and data streams.

Intended use still matters but it has evolved into a deeper conversation about context of use, data dependencies, and downstream decision impact.

Risk still drives effort but in 2026, that risk must be transparent (it always should have been but not more obvious than before), measurable, and continuously visible across the ecosystem.

Now the industry also has to think about:

• Training data quality
• Bias
• Drift
• Monitoring models after deployment
• Human oversight design

Industry has moved from validating static systems to governing learning systems.

And that’s not a small shift.

Pharma 4.0 Became Tangible

For years, Pharma 4.0 sounded visionary. Connected manufacturing. Predictive analytics. Digital twins. Autonomous decision support.

In 2026, many of those things are operational aligned with the maturity model outlined in ISPE’s Pharma 4.0™ Operating Model and reinforced by modernized lifecycle thinking in ISPE GAMP^® 5 Guide (Second Edition).

Manufacturing environments are streaming data in real time. Clinical systems are using AI to flag anomalies. Supply chains are using predictive modeling.

Which means validation had to evolve too.

Validation 4.0, an industry term increasingly aligned with ISPE’s modernization of lifecycle practices isn’t about better templates. It’s about designing assurance into digital ecosystems. Teams are no longer validating a single system in isolation. They are validating data flows, integrations, APIs, cloud services, and AI copilots interacting in real time.

That’s a completely different level of complexity.

Regulatory Note on Digital Twins (US Food and Drug Administration (US FDA) and Medicines and Healthcare products Regulatory Agency (MHRA) Context)

US FDA has clarified that use of digital twins in clinical development or decision support is evaluated within existing regulatory pathways on a case by case basis, with early sponsor engagement encouraged (e.g., during Investigational New Drug discussions) when model outputs inform regulatory decisions.

UK MHRA guidance on software and digital technologies reinforces that complex models—including simulation or digital twin components—must clearly define intended use, risk classification, data integrity controls, and oversight responsibilities when they influence regulated outcomes.

To date, there is no standalone “digital twin approval” pathway; assurance is assessed within the broader product or system regulatory framework.

The Buy vs Build AI Debate Is Heating Up

If there’s one conversation happening inside almost every organization right now, it’s this:

Do companies buy AI-enabled platforms, or do they build AI capabilities ourselves?

What became clear in 2025 was not that this debate existed, but how quickly it matured.

The last time major architectural shift—moving from on-premises systems to software-as-a-service (SaaS)—took most life sciences organizations took three to five years to truly understand the upside. The early conversations were dominated by fear: loss of control, inspection exposure, vendor dependency, data residency. It took years of lived experience before most teams stopped asking, “Is SaaS acceptable?” and started asking, “How do we optimize around it?”

In 2025, the same buy-versus-build tension around AI compressed into months.

On the surface, it still looks like a cost and speed discussion. But underneath, it’s about governance maturity. Buying AI is faster. Vendors promise embedded controls. There’s an assumption of shared responsibility. But then the hard questions surface:

How transparent is the model? How do we validate updates? Who monitors drift? What happens when the vendor pushes a silent change?

Building AI gives control. Data ownership remains internal. The architecture is understood in detail.

But now ownership also extends to:

• Model retraining
• Performance thresholds
• Data engineering
• Bias mitigation
• Lifecycle monitoring

The difference from the SaaS era is that organizations are recognizing these trade-offs earlier. They are more digitally literate. They understand shared responsibility models. They understand integration risk. They’ve lived through one transformation already.

Both paths are viable. But only if governance is ready. The real differentiator in 2026 isn’t whether you buy or build AI. It’s whether your organization understands how to govern either responsibly.

What Didn’t Change

If readers are familiar with the ISPE Digital Validation Good Practice Guide and the ISPE GAMP^® 5 Guide (Second Edition), none of this should be a surprise. These ideas can be seen as threads running continuously through the evolution of validation—concepts that haven’t disappeared, but have expanded, deepened, and taken on new dimensions as the industry has matured.

Intended Use Is Still the Anchor

No matter how advanced the technology becomes, the starting point hasn’t changed—and that’s expected.

What has changed is that AI and complex digital ecosystems have exposed just how inconsistent our understanding of intended use and predicate rules really is.

The foundational questions are still the same:

What is this system doing? What decisions depend on it? What risk does it introduce to product, patient, or data? But in 2026, we are being forced to go deeper:

What assumptions are embedded in the logic? What are the predicate rules driving outputs?

Where does automated decision-making begin and human review end?

For years, many organizations treated intended use as a sentence in a validation plan rather than as the architectural backbone of control design. Predicate rules were embedded in configuration, code, or workflow logic, rarely surfaced explicitly.

AI didn’t create this gap. It exposed it.

When systems learn, adapt, or generate outputs probabilistically, vague definitions are no longer survivable. If intended use is unclear, oversight collapses. If predicate rules are not transparent, risk cannot be meaningfully assessed.

This principle hasn’t changed.

But it has been illuminated in a way that makes the gap visible and therefore actionable.

That was true under GAMP^® 4 and reinforced in ISPE GAMP^® 5 Guide (Second Edition). It’s equally true under the 2025 ISPE AI guidance.1^, 2^, 3^, 4